With $969 million raised across two new funds, Foresite Capital plans to continue putting its money to work in data-driven healthcare companies. Foresite Capital Fund V and Foresite Capital Opportunity Fund V will invest in...

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...

ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH) in a cash and stock transaction valued at about $12 billion. The deal combines ICON’s Accellacare site network, home health services and wearables expertise...

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...

Beam will take advantage of a months-long run-up in its share price to add a key base editing delivery technology via its takeout of privately held Guide Therapeutics, providing an early exit for investors less...

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...

Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The candidate is under FDA and EMA review.  Sanofi is...

President Biden nominated Chiquita Brooks-LaSure as CMS administrator. Brooks-LaSure previously served under the Obama administration as deputy director for policy at CMS’ Center for Consumer Information and Insurance Oversight and as director of coverage policy at...

First-time CEOs of biotechs must not fall in the trap of continuing to excel in the domain areas their career success has been built on. Effectively stepping up to the chief executive role requires getting...

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes. Primmune Therapeutics Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream receptor for...